ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection

Trial Profile

ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ECOSPOR IV
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 15 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top